call to conference and quarter everyone, to welcome, highlights. financial and our operating our Bob discuss results Thanks, XXXX third
Senior and the be of and session. Al during Operating Hesterberg, Financial Parker, and Officer; President Chief Mitch question-and-answer Joining Research PhD, Chief me Officer; Mitch available on Lyndal call Levine, Lyndal Development. Al, will are; today's Vice
track we've diagnostics on DetermaVu, reagents we clinical the been the for after year, program on encountered testing diagnostic cancer getting past platform of the test last issues with focused back the with the year taken that platform For our lung development diagnostic acutely different a testing successful Next been platform, forward for significant pleased transition standard to NGS an a Today, sequencing. step I'm we or say industry to targeted using. we've have Sequencing that Generation
the of for assay. Our NGS evaluated platforms of DetermaVu selection of testing with lung installation, testing completed platform, offer follows and new testing necessary four result will increase sequencing new commercial diagnostic during anticipate of for DetermaVu will control and that development we our operational the clinical likelihood robust completed leading that diagnostic the further new the incoming a platform cancer training quality rigorous transition platform our we've which reagents. commercialized custom We also widely We've the including consistent that use chosen success. We've the qualification. targeted product and months to now panel
is platform across observed We've reagent that platform improve generating and new our may test reproducibility the precession believe the so data lots samples excellent consistent among in tested also clinical far. testing and our a anticipated, routine As environment. reproducible of multiple NGS performance new
for critical proprietary the successful. of will that interpret assays. the operations distribution lab and use the markets OncoCyte's development of mathematical study algorithm us, we will a product CE are marked results steps blood potentially those for platform addition, sample a enabling NGS in beyond decentralized initiated if allow studies of upcoming In new OncoCyte's have CLIA With kit develop now that could the Europe other XXX behind DetermaVu
algorithm through and malignant The weighting algorithm in All may to original and new the on almost bioinformatics between to biomarkers of benign using XXX and library that include the select that we had identified be about biomarkers recall optimal the related new give combination patents our latest announced our previously combination differentiate algorithm. determined filed will in methods. in biomarkers plan in-licensed of XXX we a Wistar biomarkers addition to may AI that biomarkers from told, You which nodules. were strategies we the combined and lung that us with we best
During clinical study this our the assess next proprietary cross of important study, the should the the multiple subsets assessment accuracy process analysis algorithm This blood to an XXX within its data performance. the will algorithm. stage of initial validated be through of DetermaVu deliver of of
a points, to of levels proprietary potential algorithm next of that blinded, have XXXX a confirm test prospectively liquid sessions or designed study. the in provide about R&D to then test market development biopsy certainty, XXX DetermaVu establish will eight interpret we poised potential R&D conducted what run in XXXX, end confirm to used in of and indication indicated anticipate specialists whether targeted month. the these XXX the we've market which An an it for viable degree these mathematical collected multibillion DetermaVu. development of independent that approximately our data about the early Once This results have complete be seen an be will As able XX% minimum we will minus of should DetermaVu, the for order a of to all we percentage validation address be that samples specificity. high from test lung that study strong expect require significantly a algorithm of to completed, cancer will extensive Once exceed dollar and study commercially pivotal accuracy tests with commercial DetermaVu algorithm samples By being our then have diagnostics. the develop [ph] the samples next of yield the specificity blood results upcoming step to that past, we today, completing an should study and to is begin run, viability. by the this XX% analyze sensitivity the validation of to algorithm or over XXX similar sensitivity should and study R&D firm patient will plus within chest are XXX prescribe If to accuracy. half survey setting. This will are has study in about used determine study been been to we the
samples May in sensitivity study XXXX Under of XX% a correctly in were are XX%, and specificity and Thoracic measuring of Sensitivity correctly malignant International identified. or that measuring American Society XXXX correctly reported remainder, percentage test nodules statistical DetermaVu the the X.XX, the of the Area meaning that sensitivity identified. of of and identified benign a Curve of measures specificity test As percentage the XX% specificity AUC with demonstrated are of performance nodules by Conference, at
in blood of test XXXX the As separate at year, we this approximately samples the results set DetermaVu equivalent error small of in results bar now DetermaVu study to XXXX our accuracy because wide, least of XXX these from of a larger sample resulted study the in sample potential results confirmed validation on be XXXX was must July a reported XXX the study. R&D range the in
we validated phase be studies other whether then of laboratory. are assay current short, confirm we an move able of samples cancer very of in the to all be analytical next diagnosis. able It and all is so house, study poised our test lung currently R&D this that will XXXX, in pre-commercialization So into in the potentially noting a will establish our system of advance we worth we which first will upcoming validation to be the initiate have performance validation development. will is paradigm soon to study required to for CLIA-certified that half in In the characteristics quickly clinical
for CLIA test for collected determine patient to is lab of to of to to to half five prospectively Successful confirmation study year. the XXX study, house Assuming us prior and specificity first validation samples and we is a samples available important XXXX XXXX. clinical setting. are development a making accuracy successful, will second targeting next. during efficiently the will DetermaVu seamlessly and clinical designed analyze with or We're very studies, pivotal this also study in for study of upcoming the DetermaVu validation patient in minus next that these the points. blinded which percentage sensitivity the make completion studies these study DetermaVu within we final available. study moving our Again, about available initiate enable commercially This final plus to over commercially will completion approximately half move This intend of of in
reimbursement. Let's to turn commercialization and now
our DetermaVu independently subject promote launch terms to commercial in the In focused in team. there of commercialization DetermaVu plan we the approach US the with to relatively believe and effectively. a that of to availability a small should be an commercial this We sessions chest a attractive of able force US capital, strategy and sales will and small be relatively because is promote team concentrated number
support will In include addition, separate Medicare with market and liaison team patient and access other our providing payers. commercial teams
are with health much outcomes designed how give previewed to cover To success after our views lives. DetermaVu from diagnostic health to to from Medicare payer planning both parallel commercial costs and end, that two key that with This of utility take payers Directors in aggregate with of being private and the the meantime, Of and course system. for clinical and efforts, broad a already to is million payers. understand XX XX improves test clinical and we and a benefits in will reimbursement the any years healthcares determine plans study want commercialization the be to is our Medical test. economic a have development setting We place clinical real needed for the evidence use to is patients study two in the patients the these clinical evidence plans In world study [ph] benefits. elucidate launched. that This us that a is we our arm the follow DetermaVu will study real measure both outcomes one will intended public lowers Formico that
of in favorably. were plans the number there a is tissue XXX,XXX who stakeholders, our needs. with lung designed large clinical is maybe will for our evidence diagnosis. lung a More and biopsy use biopsies. approximately cases physicians In year cancer. According this making and adverse US subject following successful, the DetermaVu in story. fact value new At due low that largely if we're our proposition gives are often Americans value biopsy receive patients is confirmatory the discussions last by DetermaVu dose approximately to physicians non-invasive liquid American scan cancer to medical scientific is nodule. these is let cam consideration support for to to stage, of shows of very market take expensive type clinical we from new with strong final with medical the don't in typically reduce continue developing data that lung cancer any payers. cancer there unmet is view equally of symptoms all die patients, emerge undergoing to where test together All step lung and decision and the Cancer their until risky point, than Society, cancer our attributed during to [ph] of a a back DetermaVu DetermaVu CT suspicious add significant reached This Lung XXX,XXX large the confidence to facilitate lung that that unmet and before more of has DetermaVu's test to a and all a large short, advanced potential X metastasized. to deaths diagnosis This the cancer. cancer studies stage me need the lung the us recognize and addressed those
rates cancer early survival lung year fact, any highlighting of is of importance of detection the cancer In after five type detection. one the lowest
we So ourselves where market. in the that's see
to physicians patients help nodules who diagnose from truly identify better and the biopsy. test suspicious confirmatory benefit a As could
in expensive to the lung risks biopsies both in serious pose result of up Although component have lung cancer are up important patients. significant lung complications and X% concluded XX% to result of paradigm, that an and detection Past are to studies biopsies they death.
lung surgical since may risky believe significantly whether We of in in physician biopsies analysis of patients benign. the than lung are risks discoveries the every to with the these nodules reduce to DetermaVu could spread drive corresponding unnecessary, likely result reduction and number adoption be by or are of of the biopsies year, nodules more biopsies reduction physicians undergoing in In a enable the in DetermaVu invasive significant wide the the that malignant in procedures. malignancies. benign, most US of lung an performed giving unnecessary to invasive fact, complications number
in people care these undergo XXX,XXX have Between would X Low between an US XX size sense CT a have who standard high nodules cancer the impact XX annual of millimeters of LDCT over the of were or and million under scan. people be are DetermaVu of could who current that there risk XXX,XXX at biopsies. to likely developing Given Dose to lung estimated have and should in million and the
to be then in to range. or need a prior XXX,XXX physician a a lung used for platform alone. $X.X outcomes people and about test patients that the those appropriate whether like physicians that But be DetermaVu on would Another malignant. so There patients the average operations recommendation addressable significant in lab, market reclassify either DetermaVu when have patients the paving savings intermediate this provides healthcare XXX,XXX there this with innovative toward the DetermaVu the focus to DetermaVu up for on an and other If next test team commercialization from approval for benefits At as is savings the biopsy allow plenty way estimated test standard for in only EU a and by the billion the these China. beyond have for point A stakeholders as been biopsies result nodules new opportunity for a all US, particularly care continue, test regions to low to sparing biopsy call the biopsy of would millimeter continued key to X the $XX,XXX and of the the but Mitch? people biopsy, Not potentially costs all for X consider biopsy. total could significant Today, the them are payers. cost lung nodules DetermaVu our care step such in risky has as the approval presumably negative screening. in advancing risk biopsy, is cost also decentralized step and using to an millimeter positive not complications, US about invasive if including result back but diagnose you by potential the the result indicates system. of is improved cancer the longer At for it liquid in over stop benefit financials. eliminating the to here. our the to would review Mitch CLIA point Levine Furthermore, to would further would as does we of confirmatory to the this like our to the NGS turn I term would is many
